RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
146 hedge funds and large institutions have $841M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 45 increasing their positions, 45 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
2% less funds holding
Funds holding: 149 → 146 (-3)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Holders
146
Holding in Top 10
1
Calls
$13.2M
Puts
$8.04M
Top Buyers
| 1 | +$31.1M | |
| 2 | +$6.19M | |
| 3 | +$5.51M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.49M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$3.25M |
Top Sellers
| 1 | -$11.8M | |
| 2 | -$6.78M | |
| 3 | -$6.64M | |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.54M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.72M |